Edition:
United Kingdom

Gensight Biologics SA (SIGHT.PA)

SIGHT.PA on Paris Stock Exchange

1.95EUR
24 Sep 2018
Change (% chg)

€-0.01 (-0.76%)
Prev Close
€1.97
Open
€2.00
Day's High
€2.00
Day's Low
€1.95
Volume
27,557
Avg. Vol
43,233
52-wk High
€7.68
52-wk Low
€1.92

Chart for

About

Gensight Biologics SA is a France-based company, which specializes in the clinical-stage biotechnology and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The Company, through I ts integrated development platform, combines a gene therapy-based approach with... (more)

Overall

Beta: --
Market Cap(Mil.): €122.62
Shares Outstanding(Mil.): 24.00
Dividend: --
Yield (%): --

Financials

  SIGHT.PA Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -- -- --
ROI: -- 1.79 14.61
ROE: -- 3.28 16.33

BRIEF-Gensight Biologics cash position slightly dips, issues update on GS010

* GenSight Biologics’ cash and cash equivalents amounted to €49.2 million as of March 31, 2018, compared to €55.4 million as of December 31, 2017

25 Apr 2018

Earnings vs. Estimates